OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Biomedical freezer maker to combine with supplier of cell and gene therapy tools
Stirling Ultracold, a developer and manufacturer of ultra-low temperature (ULT) freezers, has signed a definitive agreement to merge into BioLife Solutions to combine expertise and expand individual product offerings for biopharma research and life science customers.
The deal is expected to close in the second quarter.
BioLife, a supplier of class-defining cell and gene therapy bioproduction tools and services, plans to keep the Stirling Ultracold brand intact and maintain current staff in Athens, OH, noting “business as usual” for existing customers and partners.
The freezer company has been at the forefront of Covid-19 vaccination efforts by providing the only line of ULT freezer systems capable of storing any mRNA vaccine requiring -20°C (-4°F) to -86°C (-122.8°F) thermal protection, Stirling says. Prior to this merger, the company worked closely with many of the BioLife business lines, including Custom Biogenics Systems and SciSafe Biorepositories.